Pipeline: Regenerative Dermatology

EXPLORING POTENTIAL APPLICATION IN REGENERATIVE DERMATOLOGY

We are exploring the use of the RECELL® System technology platform for gene therapy involving genetically modified skin cells related to skin disorders such as inflammatory skin disease, other geno-dermatoses and rejuvenation. For general information about our science and technology, please contact our Medical Affairs team.

Epidermolysis Bullosa

Epidermolysis Bullosa (EB) is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death. EB is estimated to afflict approximately ~3-8 million people in the United States, [1] and there currently is no FDA-approved treatment.

Currently, AVITA Medical and scientists at the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine are collaborating on preclinical research to establish proof of concept and explore further development of a spray-on treatment of genetically modified cells for patients with EB, with potential applicability to other genetic skin disorders. The partnership pairs AVITA Medical’s patented and proprietary Spray-On Skin™ Cells technology and expertise with the Gates Center’s innovative, patent-pending combined reprogramming and gene-editing technology to allow cells to function properly.

Rejuvenation 

More than 3 million aesthetic procedures are performed in the U.S. annually aimed to improve skin tightness, texture, and evenness in skin tone. [2]


  1. Prevalence estimate for DEB from ‘Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates from the National Epidermolysis Bullosa Registry’; Fine J, JAMA Dermatol. 2016;152(11):1231-1238; Estimates based on dressing & other costs for adults and 10 year olds – ‘Management of chronic wounds in patients with dystrophic epidermolysis bullosa: challenges and solutions’, Rashidghamat and Mellerio, Chronic Wound Care Mgmt and Res, 2017, Vol :4 Pages 45—54; Genodermatoses & Rare Skin Disorders Network. Source of image: “A case of a patient with severe epidermolysis bullosa surviving to adulthood”, Hubail et al, International Journal of General Medicine, 2018, Volume 2018:11, Page 413
  2. Source: 2018 Plastic Surgery Statistics Report, https://www.plasticsurgery.org/documents/News/Statistics/2018/plastic-surgery-statistics-full-report-2018.pdf
This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.